ConductScience.org, home

Paper41998137

Neoantigens and shared MICB α3 antigen dual-targeted vaccine generates potent antitumor immunity.

Tang R and 13 others. EMBO Mol Med, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Neoantigens and shared MICB α3 antigen dual-targeted vaccine generates potent antitumor immunity. Papers, record 41998137. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41998137

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Neoantigens and shared MICB α3 antigen dual-targeted vaccine generates potent antitumor immunity.
PubMed
Journal
EMBO Mol Med
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-08-13
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tang RRuijinghttps://orcid.org/0009-0008-5129-2097
2Ye HHonghaohttps://orcid.org/0009-0002-5775-018X
3Chen GGeng
4Dong XXiuqing
5Li ZZhenli
6Lin FFangzhou
7Huang TTingfeng
8Qiu LLimanhttps://orcid.org/0000-0003-4332-1843
9Lin GGengping
10Wu MMing
11Yu HHaijun
12Zou JJianhuahttps://orcid.org/0000-0003-0718-9128
13Liu XXiaolonghttps://orcid.org/0000-0002-3096-4981
14Cai ZZhixionghttps://orcid.org/0000-0002-0912-8372

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cancer VaccinesMajor topic
Antigens, NeoplasmMajor topic
NeoplasmsMajor topic
Animals
Mice
Humans
Immunotherapy
Killer Cells, Natural
Mice, Inbred C57BL
Female
Cell Line, Tumor

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
U22A20328/82572108/82573538the National Natural Science Foundation of ChinaPubMed
2024Y9418/2024Y9420Fujian Provincial Joint Foundation for Science and Technology InnovationPubMed
2022Y2018Clinical Research Center for Infectious Diseases of Fujian ProvincePubMed
2022ZQNZD014/2024ZD01004the Major Research Projects for Young and Middle-aged Talent of Fujian Provincial Health CommissionPubMed

Source PubMed

Download CSV of grants

References54

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125858804Immune checkpoint blockade: a common denominator approach to cancer therapy.Cancer Cell2015https://conductscience.org/library/papers/25858804PubMed
241286513A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial.Nat Med2025https://conductscience.org/library/papers/41286513PubMed
331821442Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer.J Exp Med2020https://conductscience.org/library/papers/31821442PubMed
428976923TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis.Vaccines (Basel)2017https://conductscience.org/library/papers/28976923PubMed
511323673The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5.Nature2001https://conductscience.org/library/papers/11323673PubMed
628501509Designer outer membrane vesicles as immunomodulatory systems - Reprogramming bacteria for vaccine delivery.Adv Drug Deliv Rev2017https://conductscience.org/library/papers/28501509PubMed
719109134Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein.J Immunol2009https://conductscience.org/library/papers/19109134PubMed
835133159Neoantigen Immunotherapeutic-Gel Combined with TIM-3 Blockade Effectively Restrains Orthotopic Hepatocellular Carcinoma Progression.Nano Lett2022https://conductscience.org/library/papers/35133159PubMed
917325197Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis.J Exp Med2007https://conductscience.org/library/papers/17325197PubMed
1022237626Exploiting the mutanome for tumor vaccination.Cancer Res2012https://conductscience.org/library/papers/22237626PubMed
1123890059Oncology meets immunology: the cancer-immunity cycle.Immunity2013https://conductscience.org/library/papers/23890059PubMed
1222596238The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer.Br J Cancer2012https://conductscience.org/library/papers/22596238PubMed
1328187290Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Cell2017https://conductscience.org/library/papers/28187290PubMed
1429017836Emerging Insights into Noncanonical Inflammasome Recognition of Microbes.J Mol Biol2018https://conductscience.org/library/papers/29017836PubMed
1530307368High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodies.MAbs2019https://conductscience.org/library/papers/30307368PubMed
1634447945Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity.Nat Cancer2020https://conductscience.org/library/papers/34447945PubMed
1718394936NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.Immunity2008https://conductscience.org/library/papers/18394936PubMed
1829599246Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.Science2018https://conductscience.org/library/papers/29599246PubMed
1932103006c-FLIP is crucial for IL-7/IL-15-dependent NKp46+ ILC development and protection from intestinal inflammation in mice.Nat Commun2020https://conductscience.org/library/papers/32103006PubMed
2033536615IgA transcytosis and antigen recognition govern ovarian cancer immunity.Nature2021https://conductscience.org/library/papers/33536615PubMed

See all 54 referencesDownload CSV of references

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GSDMD79792PubTator's text mininghttps://conductscience.org/library/genes/79792NCBI Gene
GZMA3001PubTator's text mininghttps://conductscience.org/library/genes/3001NCBI Gene
GZMB3002PubTator's text mininghttps://conductscience.org/library/genes/3002NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41998137

GET https://conductscience.org/api/papers/v1/41998137/references?page=2